2022
DOI: 10.3390/pharmaceutics14071479
|View full text |Cite
|
Sign up to set email alerts
|

Hyaluronic Acid: Its Versatile Use in Ocular Drug Delivery with a Specific Focus on Hyaluronic Acid-Based Polyelectrolyte Complexes

Abstract: Extensive research is currently being conducted into novel ocular drug delivery systems (ODDS) that are capable of surpassing the limitations associated with conventional intraocular anterior and posterior segment treatments. Nanoformulations, including those synthesised from the natural, hydrophilic glycosaminoglycan, hyaluronic acid (HA), have gained significant traction due to their enhanced intraocular permeation, longer retention times, high physiological stability, inherent biocompatibility, and biodegra… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
7
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 21 publications
(7 citation statements)
references
References 220 publications
0
7
0
Order By: Relevance
“…SH exhibits good mucoadhesive capabilities, readily forming hydrogen bonds with glycoproteins within the aqueous layer of tears and acting as a protective coating on corneal epithelial cells. Such binding forces significantly increase the precorneal residence time of SH-based formulations ( Casey-Power et al, 2022 ). The viscosity of carriers also plays an important role in enhancing the corneal penetration ( Awwad et al, 2017 ).…”
Section: Discussionmentioning
confidence: 99%
“…SH exhibits good mucoadhesive capabilities, readily forming hydrogen bonds with glycoproteins within the aqueous layer of tears and acting as a protective coating on corneal epithelial cells. Such binding forces significantly increase the precorneal residence time of SH-based formulations ( Casey-Power et al, 2022 ). The viscosity of carriers also plays an important role in enhancing the corneal penetration ( Awwad et al, 2017 ).…”
Section: Discussionmentioning
confidence: 99%
“…Numerous studies have described how an increase in residence time decreases the rate of drug elimination favoring the bioavailability and efficacy of the formulation [45,46]. Residence time on the ocular surface is related to viscosity [47].…”
Section: Discussionmentioning
confidence: 99%
“…Residence time on the ocular surface is related to viscosity [47]. The association between efficacy and the percentage of HA present in artificial tear has been studied in preclinical and clinical studies, concluding that formulations with higher percentages of HA and higher viscosities improved the signs and symptoms of the dry eye disease because the ocular residence time was increased [45,48,49]. The optimum viscosity of an eye drop was established between 15 to 50 mPa•s [50].…”
Section: Discussionmentioning
confidence: 99%
“…From these data, it was possible to see that the viscosity remained practically constant at 2–8 °C, while on days 15 and 30, a drop was observed in those stored at −20 °C. This may be explained due to changes in polymer conformation during the freeze/thaw processes [ 64 ]. The present cysteamine compounded formulation maintained the pseudoplastic behavior of HA previously described in the literature [ 65 , 66 , 67 ] during all storage times and conditions, by decreasing its viscosity with increasing shear force, as seen in Figures S3–S5 .…”
Section: Discussionmentioning
confidence: 99%